Graphene Photothermal Adjuvant Therapy for Mild Corona Virus Disease 2019: A Prospective Randomized Controlled Trial

This is a future-proof and randomized controlled clinical study on the clinical efficacy of graphene photothermal adjuvant therapy in Corona Virus Disease 2019(COVID-19) patients with mild symptoms. The objective is to examine the effect of graphene photothermal adjuvant therapy on the time line for such Corona Virus Disease 2019 patients to achieve a negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid test result, and their duration of disease. Patients who meet study criteria will be randomized into the Grapheme adjuvant therapy combined with conventional therapy group (treatment group) and the conventional therapy only group (control group). Contrasted to the control groups, the treatment groups will undergo 30-min of graphene adjuvant therapy every day for 7 d.

Inclusion Criteria:Meet the diagnostic criteria for mild COVID-19.Patients aged 18-60 years (inclusive).No later than 48 h after testing positive and the onset of clinical symptomsSign informed consent form.Exclusion Criteria:Severe or critically patients with COVID-19.Resting heart rate over 120 beats per minute.Coronary heart disease patients with acute cardiac insufficiency.Acute exacerbation of chronic obstructive pulmonary disease（COPD）.Uncontrolled hypertension [resting systolic blood pressure(SBP) more than 180 mmHg and diastolic blood pressure(DBP) more than 90 mmHg]; uncontrolled diabetes(Random Plasma Glucose, RPG>16.7mmol/L, HbA1C>7.0%)Patients with severe cardiovascular, hepatic, renal and hematopoietic diseases.Pregnant or menstruating woman.Known or suspected history of active tuberculosis or extrapulmonary tuberculosis, patients with brucellosis, pneumonia-related illness from other causesCOVID-19 patients for the second or more timesThose who cannot cooperate due to various reasonsBody temperature: more than 38℃.